同型半胱氨酸、叶酸和尿酸在认知功能障碍诊断中的意义

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1340 KB) HTML (0 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：探讨检测同型半胱氨酸、叶酸和尿酸在认知功能障碍诊断中的意义。方法：选取阿尔茨海默病（AD）患者63例（AD组），血管性痴呆（VaD）患者56例（VaD组），轻度认知功能障碍（MCI）患者40例（MCI组），同时选取同期健康老年人45例为对照组，分别检测各组血浆中同型半胱氨酸、叶酸和尿酸水平。结果：①AD组和VaD组同型半胱氨酸水平均高于MCI组和对照组；②AD组、VaD组、MCI组3组叶酸水平均低于对照组，AD组、VaD组叶酸水平高于MCI组；③AD组尿酸水平低于VaD组、MCI组和对照组。结论：高水平的同型半胱氨酸可能参与了认知功能障碍的发展。较低水平的叶酸与认知功能障碍有关，AD患者具有较低的血浆尿酸水平。同型半胱氨酸、叶酸、尿酸水平可能与AD、VaD、MCI的发生发展有关，同型半胱氨酸、叶酸、尿酸水平的联合测定有助于认知功能障碍的诊断。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	吴甜莺1
	张雄2
	郑永克1
	王一栋1
	潘静1
	陈艳1

关键词 ：同型半胱氨酸, 叶酸, 尿酸, 阿尔茨海默病, 血管性痴呆, 轻度认知功能障碍

Abstract：Objective: To explore the significance of homocysteine, folic acid and uric acid in diagnosis of cognitive dysfunction. Methods: We selected 63 patients with Alzheimer’s disease (AD), 56 patients with vascular dementia (VaD), 40 patients with mild cognitive impairment (MIC), and 45 healthy individuals at same period as control. The levels of homocysteine, folic acid and uric acid were detected in each group. Results: ①The levels of homocysteine in AD group and VaD group were higher than those in MCI group and control group; ②The levels of folic acid in AD group, VaD group, MCI group were lower than those in control group; ③The levels of uric acid in AD group were lower than those in VaD group, MCI group and control group. Conclusion: High levels of homocysteine may be related with the pathogenesis of cognitive dysfunction. Lower levels of folic acid are related with the cognitive dysfunction. The AD patients has lower levels of uric acid. Detecting homocysteine, folic acid and combinated with uric acid is helpful for the diagnosis of cognitive dysfunction.

Key words： homocysteine folic acid uric acid Alzheimer’s disease vascular dementia mild cognitive impairment

收稿日期: 2014-11-21

作者简介: 吴甜莺（1983-），女，浙江温州人，主治医师。

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2015/V45/I8/608

[1] Song Y, Wang J. Overview of Chinese research on senile dementia in mainland China[J]. Ageing Res Rev, 2010, 9(1): 6-12.
[2] Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria[J]. Lancet Neurol, 2007, 6(8): 734-746.
[3] Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop[J]. Neurology, 1993, 43(2): 250-260.
[4] Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairent[J]. J Intern Med, 2004, 256(3): 240-246.
[5] Oulhaj A, Refsum H, Beaumont H, et al. Homocysteine as a predictor of cognitive decline in Alzheimer′s disease[J]. Geriatr Psychiatry, 2010, 25(1): 82-90.
[6] Serot J, Barbe F, Arming E, et al. Homocysteine and methyl-malonic acid concentration in cerebrospinal fluid: relation with age and Alzheimer’s disease[J]. J Neurol Neurosurg Psychiatry, 2005, 76(11): 1585-1587.
[7] Mirashi EH, Jacobsen DW, Debanne SM, et al. Plasma total homocysteine levels, dietary vitamin B6 and folate intake in AD and healthy aging[J].J Nutr Health Aging, 2003, 7(3): 160-165.
[8] Ferreccio C, Rollán A, Harris PR, et al. Gasrric cancer is related to early Helicobacer pylori infection in a high-prevalence country[J]. Cancer Epidemiol Bionmarkers Prev, 2007, 16(4): 662-667.
[9] 胡丹, 何志勇, 王小同, 等. 血浆同型半胱氨酸水平与脑梗死近期复发关系的临床研究[J]. 温州医学院学报, 2010,40(4): 371-373.
[10] 宋君如, 张怀安, 葛成东. 高同型半胱氨酸与阿尔茨海默病关系探讨[J]. 吉林医学, 2012, 33(34): 7431-7432.
[11] Mansoori N, Tripathi M, Alam R, et al. Serum folic acid and RFC A80G polymorphism in Alzheimer’s disease and vascular dementia[J]. Am J Alzheimer’s Dis Other Demen, 2014, 29(1): 38-44.
[12] Cacciapuoti F. Lowering homocysteine levels with folic acid and B-vitamins do not reduce early atherosclerosis, but could interfere with cognitive decline and Alzheimer’s disease[J]. J Thromb Thrombolysis, 2013, 36(3): 258-262.
[13] Morris MS. Homocysteine and Alzheimer’s disease[J]. Lancet Neurol, 2003, 2(7): 425-428.
[14] Corrada MM, Kawas CH, Hallfrisch J, et al. Reduced risk of Alzheimer’s disease with high folate intake: the Baltimore Longitudinal Study of Aging[J]. Alzheimers Dement, 2005, 1(1): 11-18.
[15] Ravaglia G, Forti P, Maioli F, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease[J]. Am J Clin Nutr, 2005, 82(3): 636-643.
[16] Sachdev PS. Alzheimer disease: homocysteine and alzheimer disease: an intervention study[J]. Nat Rev Neurol, 2011, 7(1): 9-10.
[17] Graham NL, Emery T, Hodges JR. Distinctive cognitive profiles in Alzheimer’s disease and subcortical vascular dementia[J]. J Neurol Neurosurg Psychiatry, 2004, 75(1): 61-71.
[18] Zuliani G, Cavalieri M, Galvani M, et al. Markers of endothelial dysfunction in older subjects with late onset Alzheimer’s disease or vascular dementia[J]. Neurol Sci, 2008,272(1-2): 164-170.
[19] Bennett S, Grant MM, Aldred S. Oxidative stress in vascular dementia and Alzheimer’s disease: a common pathology[J]. Alzheimers Dis, 2009, 17(2): 245-257.
[20] He K, Merchant A, Rimm EB, et al. Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men[J]. Stroke, 2004, 35(1): 169-174.
[21] Li Q, Yang Z, Lu B, et al. Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes[J]. Cardiovasc Diabetol, 2011, 10(1): 72.
[22] Mottillo S, Fillion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and metaanalysis[J]. Am Coll Cardiol, 2010, 56(14): 1113-1132.
[23] Cankurtaran M, Yesil Y, Kuyumcu ME, et al. Altered levels of homocysteine and serum natural antioxdants links oxidative damage to Alzheimer’s disease[J]. J Alzheimers Dis, 2013, 33(4): 1051-1058.
[24] Kawamoto R, Tabara Y, Kohara K, et al. Synergistic influence of age and serum uric acid on blood presure among community-dwelling Japanese women[J]. Hypertens Res, 2013, 36(7): 634-638.
[25] Chen X, Guo X, Huang R, et al. Serum uric acid levels in patients with Alzheimer’s disease: a meta-analysis[J]. Plos One, 2014, 9(4): e94084.
[26] Polidori MC, Mattioli P, Aldred S, et al. Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia[J]. Dement Geriatr Cogn Disord, 2004, 18(3-4): 265-270.
[27] Rinaldi P, Polidori MC, Metastasio A, et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer’s disease[J]. Neurobiol Aging, 2003, 24(7): 915-919.